← All diseases Cancer

Mesothelioma

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest level of evidence only (25)Meta-analysis (7)Treatment guideline (2)Systematic review (9)Phase 3 study (5)Randomized trial (2)Clinical trial (594)Review article (165)Early study (phase 1 or 2) (48)Single patient description (165)Laboratory or animal study (30)Commentary or editorial (70)Concerns have been raised (1)Retracted publication (1) Studies currently recruiting participants only (33)

Filter

Publications and studies (1696)

• Pressurized intrathoracic aerosol chemotherapy (PITAC) for malignant pleural mesothelioma-ex vivo evaluation of optimal treatment conditions and comparison with hyperthermic intrathoracic chemotherapy (HITOC). (2026/05/31) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Pleural Well-differentiated Papillary Mesothelial Tumor Presenting with Recurrent Pneumothorax and Pleural Effusion: A Case Report]. (2026/05/20) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Malignant Mesothelioma Diagnosed From a Spermatic Cord Lesion After Inconclusive Thoracoscopy: A Case With Concomitant Pleural and Peritoneal Involvement. (2026/05/19) ♡
• BAP-1 in the diagnosis of malignant pleural mesothelioma. (2026/05/01) ♡
• DNA-junction-based personalized liquid biopsy assays could inform management of aggressive endometrial cancer. (2026/05/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Malignant Mesothelioma Extending from Peritoneum to Pleura: A Diagnostic Challenge and Case Report. (2026/04/27) ♡
• Multiomic, Histologic, and scRNA-seq Profiling of Pleural Mesothelioma Reveals Negative Prognosis Associated With a Novel Uncommitted Molecular Phenotype. (2026/04/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC. (2026/04/01) ♡
• Rethinking 'extreme' cytoreductive surgery in malignant peritoneal mesothelioma. (2026/04/01) ♡
• Diagnostic potential of a novel immunohistochemical marker, GFPT2, in differentiating mesothelioma from its morphological mimics. (2026/04/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Cytopathologic Features of Metastatic Malignant Mesothelioma With SMARCB1 (INI-1) Deficient Diagnosed by Ultrasound-Guided Fine-Needle Aspiration: A Case Report. (2026/04/01) ♡
• Targeting key proteins of pleural mesothelioma using plumbagin-indole-3-propionic acid ester: Insights from network pharmacology, molecular dynamics simulation and machine learning-based analysis. (2026/04/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Primary diffuse malignant epithelioid peritoneal mesothelioma of the greater omentum in an asbestos-naive patient: a case report. (2026/03/26) ♡
• Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial. (2026/03/16) ♡
• Cytoreductive surgery and HIPEC: A 10-year single-center retrospective cohort study. (2026/03/01) ♡
• Preparation and anti-tumor applications of universal umbilical cord blood-derived, mesothelin-targeted CAR-T cells. (2026/03/01) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC. (2026/03/01) ♡
• Targeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient pleural mesothelioma. (2026/02/28) ♡
• A proteomics approach to identify predictive blood biomarkers for pleural mesothelioma in prospective cohorts. (2026/02/20) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Diagnostics of lung diseases based on small specimens : Biopsies and cytology]. (2026/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Mesothelin in solid tumors: biology, biomarker utility, and therapeutic targeting. (2026/02/01) ♡
• Impact of hyperthermic intrathoracic chemotherapy during cytoreductive surgery with diaphragmatic resection. (2026/02/01) ♡
• Regulation of BAP1 activity by novel cancer-associated glutamate residues through ubiquitin binding and PARylation. (2026/01/25) ♡
• Projecting future mortality risk of pleural mesothelioma in Italy (2020-2034): Bayesian age-period-cohort analysis over 40 years of death registration. (2026/01/16) ♡
• Clinical application of confocal laser endomicroscopy in the diagnosis of malignant pleural effusion. (2026/01/12) ♡
• Burden and trends of cancer attributable to occupational asbestos exposure in China from 1990 to 2021. (2026/01/05) ♡
• ASPHD1 Is a tumor-suppressive and prognostic marker in glioma. (2026/01/02) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Uncommon Spindle Cell Tumors of the Pleura. (2026/01/01) ♡
• Global patterns and trends in mesothelioma incidence: A retrospective cross-sectional study. (2026/01/01) ♡
• Merlin Immunohistochemistry Is Useful in the Differential Diagnosis of Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia. (2026/01/01) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Locoregional therapies in advanced and recurrent pleural mesothelioma: A systematic review. (2026/01/01) ♡
• Prognostic Value of the Hemoglobin, Albumin, Lymphocyte, Platelet Score in Metastatic Mesothelioma: A Retrospective Study. (2026/01/01) ♡
• Cardiac Cancer: An Evidence-Based Study of Occurrence. (2026/01/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma (2026-08-11) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma (2026-08-11) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 (2026-08-11) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma (2026-08-11) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Mesothelioma Early Detection by VOCs (2026-08-10) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy (2026-08-10) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. SW-682 in Advanced Solid Tumors (2026-08-10) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors (2026-08-10) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome (2026-08-07) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma (2026-08-07) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma (2026-08-05) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors (2026-08-05) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) (2026-08-04) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease (2026-08-04) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma (2026-08-04) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma (2026-08-04) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (2026-08-04) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.